Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin- converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009; 20: 2641 2650. 109. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70: 2116 2123. 110. Toto RD. Aldosterone blockade in chronic kidney disease: can it improve outcome? Curr Opin Nephrol Hypertens 2010; 19: 444 449. 111. Rebello S, Compain S, Feng A et al. Effect of cyclosporine on the pharmacokinetics of aliskiren in healthy subjects. J Clin Pharmacol 2011; 51: 1549 1560. 112. Parving HH, Persson F, Lewis JB et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433 2446. 113. Parving HH, Brenner BM, McMurray JJ et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009; 24: 1663 1671. 114. US Food and Drug Administration. FDA drug safety communication: New warning and contraindication for blood pressure medicines containing aliskiren (Tekturna). (http://www.fda.gov/Drugs/DrugSafety/ ucm300889.htm). 115. Ernst ME, Moser M. Use of diuretics in patients with hypertension. N Engl J Med 2009; 361: 2153 2164. 116. Bakris G, Molitch M, Hewkin A et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592 2597. 117. National Clinical Guideline Center. Hypertension. The Clinical Manage- ment of Primary Hypertension in Adults. Clinical Guideline 127. Commis- sioned by the National Institute for Health and Clinical Excellence, 2011. 118. Gallagher M, Perkovic V, Chalmers J. Diuretics: a modern day treatment option? Nephrology (Carlton) 2006; 11: 419 427. 119. Duarte JD, Cooper-DeHoff RM. Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. 